ID   BEL-A 5x KO
AC   CVCL_C0XI
SY   5x KO BEL-A; 5x KO #4 BEL-A
DR   PRIDE; PXD009291
DR   Wikidata; Q114310729
RX   CelloPub=CLPUB00710;
RX   PubMed=29700043;
CC   Characteristics: Completely deficient in blood groups encoded by five different genes that encode antigens responsible for the most common transfusion incompatibilities.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; 4035; ACKR1.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; 4012; FUT1.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; 4703; GYPB.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; 6308; KEL.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; 10006; RHAG.
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P03126; Human papillomavirus type 16 protein E6.
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P03129; Human papillomavirus type 16 protein E7.
CC   Transformant: NCBI_TaxID; 333760; Human papillomavirus type 16 (HPV16).
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Genome sequenced.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
CC   Cell type: Mononuclear cell; CL=CL_0000842.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_C0XH ! BEL-A 4x KO
SX   Sex unspecified
AG   Adult
CA   Transformed cell line
DT   Created: 22-09-22; Last updated: 10-09-24; Version: 6
//
RX   CelloPub=CLPUB00710;
RA   Hawksworth J.S.;
RT   "CRISPR-Cas9 gene editing in an immortalized erythroid cell line for
RT   production of engineered red blood cells.";
RL   Thesis PhD (2019); University of Bristol; Bristol; United Kingdom.
//
RX   PubMed=29700043; DOI=10.15252/emmm.201708454; PMCID=PMC5991592;
RA   Hawksworth J.S., Satchwell T.J., Meinders M., Daniels D.E., Regan F.,
RA   Thornton N.M., Wilson M.C., Dobbe J.G.G., Streekstra G.J.,
RA   Trakarnsanga K., Heesom K.J., Anstee D.J., Frayne J., Toye A.M.;
RT   "Enhancement of red blood cell transfusion compatibility using
RT   CRISPR-mediated erythroblast gene editing.";
RL   EMBO Mol. Med. 10:e8454.1-e8454.11(2018).
//